1. European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) July 2015

2. What is EFSPI? EFSPI = European Federation of Statisticians in the Pharmaceutical Industry Founded in 1992 EFSPI is an “umbrella”, non-profit making organisation A federation of National European Groups Now have 10 national groups No individual members Our national organisations collectively represent 2800 members Each organisation has 2 members on the EFSPI Council Website: www.efspi.orgwww.efspi.org 2

3. BelgiumSBS/BVS DenmarkDSBS Finland SSL FranceSFdS GermanyAPF ItalyBIAS NetherlandsPSDM SwedenFMS SwitzerlandBBS United Kingdom PSI EFSPI members 3

4. BelgiumSBS/BVS DenmarkDSBS Finland SSL FranceSFdS GermanyAPF ItalyBIAS NetherlandsPSDM SwedenFMS SwitzerlandBBS United Kingdom PSI EFSPI Council Members Emmanuel Quinaux, An Vandenbosch Arne Haahr Andreasen, Birgitte Biilmann Rønn Teppo Huttunen, Sami Virtanen François Aubin, Maylis Coste Christoph Gerlinger, Frank Langer Giampaolo Giacovelli Paolo Morelli Egbert Biesheuvel, Stefan Driessen Mattis Gottlow, Magnus Kjaer Marisa Bacchi, Hans Ulrich Burger Mark Morris, Chrissie Fletcher 4

5. EFSPI Objectives To promote professional standards of statistics and the standing of the statistical profession in the pharmaceutical industry To offer a collective expert input on statistical matters to national and international authorities and organisations To exchange information on and harmonise attitudes to the practise of statistics in the European Pharma Industry and within member groups 5

6. EFSPI Officers and Key Roles ( 2015) President / Communications – Chrissie Fletcher Vice-President – Marisa Bacchi Treasurer – Birgitte Biilmann Rønn Scientific Lead – Egbert Biesheuvel Regulatory Lead – Christoph Gerlinger Statistical Leaders Chair – Stefan Driessen Website – Francois Aubin EFSPI Executive Office – Julie Mellish, KSAM 6

7. EFSPI Activities Regulatory Affairs (joint committee with PSI) co-ordinates review of regulatory guidance within EU Statistical Community Works with Scientific to identify topics for scientific debate Scientific Organise series of scientific forums for discussion and collaboration Share and disseminate materials to EU Statistical Community Communications Distribute quarterly newsletters, and seek collaborations with other relevant associations Statistical Leaders Meeting 7

8. EFSPI – Regulatory affairs For example input in FDA guideline on non-inferiority 8

9. EFSPI – Regulatory affairs For example viewpoint on data transparency 9

10. EFSPI – Scientific Affairs 2015 (current plan): EFSPI/BBS Health Technology Assessment meeting PSI/EFSPI Estimands and sensitivity analyses meeting EFSPI Late Phase Dose finding studies meeting EFSPI Biomarkers and subgroup analyses meeting 2014: EFSPI Health Technology Assessment meeting BBS/EFSPI Data transparency meeting 2013: EFSPI/BBS Health Technology Assessment meeting EFSPI/PSI Structured benefit-risk assessment meeting EFSPI Survival analysis and its applications meeting EFSPI Data transparency workshop 10

11. EFSPI – Communications www.efspi.org 11 Monthly newsletters New website

12. Statistics Leaders Meetings Forum of senior statistics leaders in EU from across the industry (managers and key opinion leaders in statistics) Meets annually (since 2010) to discuss and address strategic challenges, enabling networking and exchange of information on key developments in the industry Opportunities for SIGs to bring topics for scientific discussion and seek advice/direction Share key news and use email distribution list to seek input between meetings, may hold adhoc teleconferences as needed 12

13. EU Statistical Leaders – key topics discussed in previous meetings 13 Integrated Data Analysis Leadership and managing through change Data transparency Emerging trends in statistics

14. Current SIGs* Biomarker (leader = Athula Herath, heratha@MedImmune.com )heratha@MedImmune.com Benefit-risk (leader = Alexander Schacht, schacht_alexander@lilly.com )schacht_alexander@lilly.com Health Technology Assessment, HTA (leader = Chrissie Fletcher, fletcher@amgen.com )fletcher@amgen.com Integrated Data Analysis (leader = Byron Jones, byron.jones@novartis.com) byron.jones@novartis.com Medical Devices (leader = Roland Marion-Gallois, roland.marion-gallois@medtronic.com )roland.marion-gallois@medtronic.com Modelling & Simulation (leader = Chris Campbell, ccampbell@mango-solutions.com )ccampbell@mango-solutions.com Real World data (leader = George Quartey, quarteyg@gene.com )quarteyg@gene.com Toxicology (leader = Gareth Thomas, ThomasG@UKOrg.Huntingdon.com)ThomasG@UKOrg.Huntingdon.com * Majority of SIGs formed under leadership of PSI and subsequently expanded to include EFSPI members 14

15. EFSPI working group on data sharing Lead Sally Hollis (AZ) and Uli Burger (Roche) Objectives: –To identify and prospectively prioritize statistical issues in data transparency –To co-ordinate statistical contributions across Europe to the data transparency debate –To disseminate relevant information on the topic across the statistical community –To develop and share a vision of the potential longer term impact of data transparency. 15

16. EFSPI working group on data sharing Five work streams –Providing continuous input in EMA/EFPIA (Christoph Gerlinger, Bayer, Chrissie Fletcher, Amgen) –Recommendations for re-analysis practices (Chrissie Fletcher, Amgen, Sally Hollis, AstraZeneca) –Future impact on biostatistics (Nick Manamley, Amgen) –Minimal requirements for data sharing (Rebecca Sudlow, Roche, Janice Branson, Novartis) –Ensuring patient data confidentiality (Katherine Tucker, Roche) 16

17. European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) For more information, visit our website: www.efspi.org